Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Triton in connection with the acquisition of Prenax
Mandate

Vinge advises Triton in connection with the acquisition of Prenax

July 01, 2025 M&A Contentious Regulatory Banking and Finance Commercial Agreements Employment and Benefits IT, Telecommunications and Outsourcing Data protection and processing of personal data Intellectual Property Real Estate and Construction

Vinge has advised Triton Smaller Mid Cap Fund II in connection with the acquisition of Prenax from LBO France and certain minority shareholders.

Prenax is a leading subscriptions management service provider. The company was founded in 1993 and today manages the administration of over 340,000 subscriptions on behalf of its clients. Prenax has offices in 11 countries across the UK & Benelux, the Nordics, Southern Europe, the US, and Australia. 

The transaction is subject to regulatory approvals.

Vinge’s team mainly consisted of Johanna Wiberg, Egil Svensson, Michella Lina Said and Hedvig Merkel (M&A), David Olander and Lovisa Arpi (Regulatory), August Ahlin (Banking and Finance), Mario Saad and Jacob Eberil (Agreements), William Karo Persson (Employment), Carla Håkansson (IT), Siri Blomberg (GDPR), Arvid Axelryd and Melinda Oldenburg (IP), Simon Gille-Johnson (Real Estate), Hayaat Ibrahim (Compliance), Diana Kanold (Transaction Support Coordinator).

Read the client’s press release.

Related

Vinge advises Sobro on its investment in Västkustens Konstruktionsbyrå

 Västkustens Konstruktionsbyrå has decided to broaden its ownership structure by bringing in Sobro as a new co-partner and majority shareholder. The founders will remain with the company as the CEO and CTO respectively, and as significant shareholders. Västkustens Konstruktionsbyrå is an engineering consultancy company based in Gothenburg with cutting-edge expertise in project management, civil engineering and design.
April 23, 2026

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of SEK 350 million before transaction costs.
April 22, 2026

Vinge has advised Alder on the establishment of Alder Strategic Opportunities Fund I and on a fund credit facility agreement in connection with the fundraising

 Vinge has advised Alder on the establishment of the continuation fund Alder Strategic Opportunities Fund I AB. In connection with the establishment, the fund acquires the portfolio companies SI and SMG from Alder II. Vinge also advised Alder on the entering into of a fund credit facility agreement with SEB.
April 20, 2026